MedTrace Logo

Predictive Value of Infarction Volume on Hemorrhagic Transformation in Ischemic Stroke/TIA With Non-valve Atrial Fibrillation(NVAF) Patients Using Rivaroxaban

NCT03772457 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2023-04-18

No results posted yet for this study

Summary

This study was aimed at patients with newly diagnosed stroke / TIA associated with nonvalvular atrial fibrillation. We will observe the effect of early using rivaroxaban anticoagulation on hemorrhagic transformation, and explore the predictive value of multi-mode MRI infarct volume / MMP-9 on hemorrhagic transformation after anticoagulation therapy.

Conditions

  • Cerebrovascular Stroke
  • Intracranial Hemorrhages
  • Anticoagulant
  • Matrix Metalloproteinases

Interventions

DRUG

Rivaroxaban

new oral anticoagulant molecules which is the selective factor Xa inhibitor

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • Taizhou Hospital

    collaborator OTHER

  • Zhuji People's hospital

    collaborator UNKNOWN

  • Shaoxing People's Hospital

    collaborator OTHER

  • Jinhua Central Hospital

    collaborator OTHER

  • HaiyanPeople's hospital

    collaborator UNKNOWN

  • Wenzhou Central Hospital

    collaborator OTHER

  • The Central Hospital of Lishui City

    collaborator OTHER

  • Dongyang People's Hospital

    collaborator OTHER

  • The Third Affiliated Hospital of Wenzhou Medical University

    collaborator OTHER

  • Second Affiliated Hospital, School of Medicine, Zhejiang University

    lead OTHER

Principal Investigators

  • Min Lou, PhD · Second Affiliated Hospital, School of Medicine, Zhejiang University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-18
Primary Completion
2023-12-31
Completion
2024-12-31
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03772457 on ClinicalTrials.gov